Johnson & Johnson (JNJ) Interest Expenses (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Interest Expenses came in at $281.0 million in Q2 2026, down 8.77% year-over-year from $308.0 million in Q2 2025, and up 3.31% quarter-over-quarter from $272.0 million in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Interest Expenses (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Interest Expenses across 18 years of filings, most recently posting $281.0 million for Q2 2026.
- In Q2 2026, Interest Expenses fell 8.77% year-over-year to $281.0 million; the TTM figure through Jun 2026 stood at $1.0 billion (up 20.19% YoY), while the FY2025 annual figure was $971.0 million, up 28.61% from the prior year.
- Interest Expenses came in at $281.0 million for Q2 2026 at Johnson & Johnson, up from $272.0 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $308.0 million in Q2 2025 to a low of $10.0 million in Q2 2022.
- Average Interest Expenses over 5 years is $183.5 million, with a median of $198.5 million recorded in 2024.
- Year-over-year, Interest Expenses tumbled 84.13% in 2022 and surged 2020.0% in 2023.
- Over 5 years, Interest Expenses stood at $51.0 million in 2022, then surged by 196.08% to $151.0 million in 2023, then dropped by 9.27% to $137.0 million in 2024, then surged by 56.2% to $214.0 million in 2025, then surged by 31.31% to $281.0 million in 2026.
- Per Business Quant data, the three most recent Interest Expenses figures were $281.0 million in Q2 2026, $272.0 million in Q1 2026, and $214.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -462.00 Mn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -333.60 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 23.78 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 582,000.00 |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 2.90 Mn |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 2.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 281.00 Mn |
| Mar 29, 2026 | 272.00 Mn |
| Dec 28, 2025 | 214.00 Mn |
| Sep 28, 2025 | 245.00 Mn |
| Jun 29, 2025 | 308.00 Mn |
| Mar 30, 2025 | 204.00 Mn |
| Dec 29, 2024 | 137.00 Mn |
| Sep 29, 2024 | 193.00 Mn |
| Jun 30, 2024 | 270.00 Mn |
| Mar 31, 2024 | 155.00 Mn |
| Dec 31, 2023 | 151.00 Mn |
| Oct 1, 2023 | 192.00 Mn |
| Jul 2, 2023 | 217.00 Mn |
| Apr 2, 2023 | 212.00 Mn |
| Jan 1, 2023 | 153.00 Mn |
| Oct 2, 2022 | 51.00 Mn |
| Jul 3, 2022 | 38.00 Mn |
| Apr 3, 2022 | 10.00 Mn |
| Oct 3, 2021 | 20.00 Mn |
| Jul 4, 2021 | 40.00 Mn |